发现HC-7366:一种口服生物可用且有效的GCN2激酶激活剂
Christopher G Thomson1, Thomas D Aicher2, Weiwei Cheng3
1Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K.
Journal of medicinal chemistry
|March 26, 2024
概括
研究人员开发了HC-7366,一种用于癌症治疗的GCN2激酶激活剂. 这种优化的化合物显示了改进的特性,导致在临床前模型中抑制瘤生长.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 一般控制不可抑制的2 (GCN2) 激酶是癌症治疗的目标.
- 以前的激活剂在透性和药理动力学特性方面存在局限性.
研究的目的:
- 开发具有改进药物样性质的新型GCN2激酶激活剂.
- 评估这些化合物的有效性,包括HC-7366,作为抗瘤剂.
主要方法:
- 基于英达的GCN2激活剂的药用化学优化.
- 在体外测试GCN2激酶功效和PERK选择性.
- 在动物体内药理动力学和ADME研究.
- 在异种移植瘤模型中的有效性评估.
主要成果:
- 优化产生了具有增强透性的化合物,并保持了GCN2强度和PERK选择性.
- 在老鼠和小鼠中,HC-7366的体内暴露被证明是强大的.
- 在异种移植模型中,HC-7366的使用导致显著的瘤生长抑制.
结论:
- 开发的GCN2激活剂,以HC-7366为例,代表了一类有前途的抗瘤治疗药物.
- 改善ADME特性对于实现体内疗效至关重要.
- 激活GCN2通路是癌症治疗的可行策略.
相关概念视频
01:25cAMP-dependent Protein Kinase Pathways
6.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.3K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K